Description
The outcome of patients diagnosed with multiple myeloma has improved significantly over the past decade. Novel agents used in combination have extended median survival from just 3 years to now 8-10 years. Moreover responses are deeper and more durable. MRD negativity is evolving to be a highly important outcome that may be a surrogate for overall survival.
Objectives
- Review current diagnosis and prognostication for myeloma.
- Understand current treatment strategies.
- Recognize the importance of MRD testing in MM.